Status:

UNKNOWN

The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia

Lead Sponsor:

Sun Yat-sen University

Conditions:

Acute Lymphoblastic Leukemia

Eligibility:

All Genders

Up to 16 years

Phase:

PHASE4

Brief Summary

The Guangdong work group of childhood acute lymphoblastic leukemia (ALL) therapy was set up in October 2002. The investigators treated the childhood ALL with a GZ2002 protocol since the year 2002, and...

Detailed Description

The modification includes: 1. In the induction phase, the agent of dexamethasone 6 mg/m2 is used instead of prednisone after prednisone prophase. 2. The phase "CAM" is 2 weeks for SR patients and 4 w...

Eligibility Criteria

Inclusion

  • Cytologically proven acute lymphoblastic leukemia (ALL)
  • No relapse of a previously unrecognized ALL
  • Patients must meet one of the following risk criteria:
  • Standard-risk (SR) group meeting all of the following criteria:
  • Blasts \< 1,000/μL in peripheral blood (PB) on day 8
  • Aged 1 to \< 6 years
  • Initial WBC \< 20,000/μL
  • M1 (5%) or M2 (≥ 5% to \< 25%) blasts in bone marrow on day 15;
  • M1 marrow on day 33.
  • Intermediate-risk (IR) group meeting all of the following criteria:
  • Aged \< 1 or ≥ 6 years and/or WBC ≥ 20,000/μL
  • Blasts \< 1,000/μL in PB on day 8
  • M1 or M2 marrow on day 15
  • M3 (≥ 25%) marrow on day 15 OR meets SR criteria but M3 marrow on day 15 and \*M1 marrow on day 33.
  • High-risk (HR) group meeting ≥ 1 of the following criteria:
  • Meets IR criteria and M3 marrow on day 15 (not SR and M3 on day 15)
  • Blasts ≥ 1,000/μL in PB on day 8
  • M2 or M3 marrow on day 33
  • Translocation t(9;22) \[BCR/ABL+\] (Philadelphia chromosome-positive) or t(4;11) \[MLL/AF4+\].

Exclusion

  • No Down syndrome
  • No other major disease that prohibits study treatment (e.g., severe congenital heart disease)
  • Not requiring significant therapy modification owing to study therapy associated complications
  • No complications due to other interventions
  • No one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2018

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT00846703

Start Date

July 1 2008

End Date

December 1 2018

Last Update

March 8 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The second affiliated hospital of Sun Yat-sen University

Guangzhou, Guangdong, China, 510000